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Abstract Objectives: Tissue damage caused by ischemia/reperfusion injury (IRI) of the intes-
tine may lead to organ dysfunction in several clinical conditions, and is associated with
increased incidence of chronic rejection after transplantation. Heme oxygenase-1 (HO-1) is
a stress-inducible protein capable of modulating inflammation, oxidative stress, and cell death.
The aim of the present study was to assess the effects of HO-1 upregulation on intestinal IRI.
Methods: Lewis rats (seven groups, nZ 6 each) underwent intestinal warm ischemia induced by
clamping the superiormesenteric artery andby ligating the inferiormesenteric artery for 60 min.
After 120 or 240 min of reperfusion, tissue samples were collected for analysis. Cobalt protopor-
phyrin (CoPP)was administered IPat 10 or 20 mg/kg 24 hbefore IRI, to induceHO-1 upregulation.
Control animals received vehicle alone. Tissue injury measurements included the following: his-
tological changes, tissue myeloperoxidase (MPO) activity, nitrate/nitrite levels, and IL-6 levels.
Results: A significant HO-1 upregulation was demonstrated in pre-treated animals (p< 0.05, 95%
CI:0.84 to0.05). Intestinal IL-6 mRNA expression levels were significantly reduced in animals
treated with CoPP 20 mg/kg after 240 min of IRI (p< 0.05, 95% CI: 0.09e2.25). Significant
reduction in MPO activity and NO products was observed in treated animals when compared
to controls (p< 0.01, 95% CI: 0.07e0.24 and p< 0.01, 95% CI: 5.58e12.75, respectively).
Conclusions: Induction of HO-1 by CoPP administration before IRI was resulted in a significant
reduction of intestinal tissue injury. Developing strategies to induce HO-1 upregulation before
surgery will be important to reduce IRI in the clinical setting.
ª 2006 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
* This work was supported by the Department of Surgery of the University of Miami School of Medicine, Miami, Florida, and by the Diabetes
Research Institute Foundation Hollywood, Florida.
* Corresponding author. Department of Surgery, University of Southern California Keck School of Medicine, 1200 North State Street, Room
18140, Los Angeles, CA 90033, United States. Tel.: þ1 323 226 4222; fax: þ1 323 226 4244.
E-mail addresses: nwasserberg@surgery.usc.edu, nwasserberg@gmail.com (N. Wasserberg).
c NW and AP equally contributed to this work.1743-9191/$ - see front matter ª 2006 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijsu.2006.06.001
HO-1 upregulation reduces intestinal IRI 217Introduction
Ischemia/reperfusion injury (IRI) is characterized by severe
tissue damage that follows the local production of proin-
flammatory cytokines, chemokines, and reactive oxygen
species (ROS). IRI profoundly influences the fate of the
targeted organ,1 and it plays a critical role in the induction
of organ dysfunction. Significant morbidity and high mortal-
ity rates have been described after IRI in many pathological
conditions, including surgery for small bowel obstruction,
abdominal aortic aneurysm, coronary bypass, cardiac in-
farct, mesenteric ischemia, trauma, and hemorrhagic and
septic shock.2e4 In organ transplantation, IRI has been
associated with early graft dysfunction and primary non-
function, and with an increased incidence of chronic graft
rejection episodes that affect graft survival.5 Although
reperfusion is essential to restore intestinal function after
ischemic events, it worsens the injury following ischemia.6
The complex mechanisms by which IRI results in tissue
damage involve the activation of inflammatory mediators,
including production of tumor necrosis factor-a (TNF-a),
interleukin-6 (IL-6), upregulation of b2-integrins and endo-
thelial adhesion molecules, triggering of the coagulation
cascade, and complement activation.1,7,8 These events
result in the amplification of local inflammation, with
recruitment and accumulation of activated inflammatory
cells, mainly polymorphonuclear (PMN) cells, which exert
their cytotoxicity by releasing myeloperoxidase (MPO).8
Furthermore, the local production of oxidative stress medi-
ators, including nitric oxide (NO) and ROS, contribute to ex-
tend tissue injury.9,10 The profound alterations of intestinal
integrity and function include mucosal damage and
increased intestinal permeability which associated with in-
creased risk of bacterial translocation and with occurrence
of multiple organ dysfunctions.1,11 Recent data point to-
ward the role of the innate autoimmune response (namely
natural IGM and the complement system) in IRI.12 These
data are supported by findings that a single natural anti-
body prepared from a panel of B-1 cell hybridomas can
restore injury in antibody deficient mice,13 and by a demon-
stration that showed reduction in post-myocardial infrac-
tion injury after pre-treatment with a complement C3
inhibitor in a rat model.14 Defining strategies to prevent
early inflammatory events mediating IRI might represent
a viable option to improve intestinal function and survival,
reducing tissue injury and its dreadful sequelae (e.g. multi-
ple organ dysfunctions).
Heme oxygenase-1 (HO-1) is a stress-inducible protein
present in many mammalian cell types.15 Various stimulants
can induce upregulation of HO-1 protein expression, includ-
ing hemolysis, inflammatory cytokines, and oxidative
stress.15 Heme oxygenase-1 is the rate-limiting enzyme of
heme degradation into free iron, carbon monoxide and bil-
iverdin, which is readily converted into bilirubin.15 Induc-
tion of HO-1 upregulation has been reported to reduce
tissue damage after IRI in various organs,16 such as brain,17
lung,18 and liver19; however, data on the protective effect
of HO-1 upregulation on small bowel IRI are still limited.
Although the mechanisms by which HO-1 upregulation
exerts, its cytoprotective effects have not been completely
elucidated.15,20 The central hypothesis focuses on its anti-inflammatory, anti-apoptotic, and antioxidant effects me-
diated by the by-products of heme degradation, carbon
monoxide (CO), biliverdin, and bilirubin, and possibly via
MAPK-p38.16,21e23
In the present study, we evaluated the effects of HO-1
induction before IRI on intestinal damage. Intestinal IRI was
induced in rats treated with cobalt protoporphyrin (CoPP),
a powerful HO-1 inducing agent. Our data demonstrate that
CoPP-mediated HO-1 upregulation can significantly reduce
IRI-related intestinal tissue damage.
Materials and methods
Animals
Eight-week-old inbred male Lewis rats weighting 200e250 g
(Harlan Sprague Dawley Inc., Indianapolis, IN) were housed
in the animal facility at the University of Miami School of
Medicine, and had free access to water and rat chow. All
animal manipulations were conducted under protocols
approved by the University of Miami School of Medicine
Animal Care and Use Committee.
Rat model for the induction of intestinal IRI
Animals were fasted overnight before surgery. A midline
laparotomy was performed under general anesthesia (Iso-
fluorane, Abbott Labs-Animal Health, Abbot Park, IL). The
inferior mesenteric artery (IMA) was isolated and ligated at
its origin from the aorta. The superior mesenteric artery
(SMA) was dissected, free at its aortic origin, and occluded
with an atraumatic micro-vascular clamp. The abdominal
incision was sutured, and animals were kept under anes-
thesia during the following 60 min of warm intestinal ische-
mia. At this time, the incision was reopened and the
arterial clamp was removed. The intestine was inspected
for complete reperfusion (e.g. pulse, color, peristalsis,
and warmth). The abdominal muscular layer and skin
were then sutured, and the animals were awakened. After
either 120 or 240 min of reperfusion, animals were sacri-
ficed, and tissues were harvested for the analysis of tissue
damage.
Experimental design
Cobalt protoporphyrin IX chloride (CoPP; Sigma, St. Louis,
MO) was freshly prepared by dissolving it with 0.1 N NaOH
and diluting 1:1 v/v in 0.9% NaCl; the pH was adjusted to
7.4 and the solution was sterilized by filtration (0.22 mm).
Animals were given a single intraperitoneal (IP) injection
of either 10 mg/kg (nZ 12) or 20 mg/kg (nZ 12) of CoPP
24 h before the induction of intestinal warm ischemia.
Animals receiving vehicle alone served as controls (nZ 12).
Tissues obtained from additional animals that were
treated with the same schedule of CoPP 10 mg/kg (nZ 5),
20 mg/kg (nZ 5), or vehicle alone (nZ 5) but not subjected
to IRI, were evaluated for HO-1 protein expression 24 h
after injection, by western blot (WB) analysis. Tissue sam-
ples were fixed in either 10% buffered formalin or snap-
frozen and were stored at 80 C. Serum samples were
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and were stored at 80 C until assay.
Determination of HO-1 expression by
western blot analysis
Frozen tissues were thawed in lysis buffer (330 mM NaCl,
50 mM TriseHCl pH 7.6, 0.5% Triton X-100, leupeptin
10 mg/ml, aprotinin 10 mg/ml, phenyl-methyl-sulphonyl
fluoride 1 mM, iodacetamide 1.8 mg/ml, all were from
Sigma), mechanically homogenized, and incubated on ice
for 30 min, with intermittent vortexing. Tissue lysates
were centrifuged at 13,000 rpm for 15 min at 4 C, and
pellets were discarded. Protein concentration of the super-
natants was assessed by a bicinchoninic acid-based colori-
metric quantitation assay (micro BCA kit; Pierce,
Rockford, IL). Twenty micrograms of proteins was resus-
pended in loading buffer 1:5 v/v (0.5 M TriseHCl with
0.4% sodium dodecyl sulfate pH 6.8, 4 M glycerol, 600 mM
dithiothreitol, 0.001% bromophenol blue), boiled for
3 min, and were loaded in a 1.5-mm thick 12% polyacryl-
amide separating gel. Prestained standards (Kaleidoscope;
Biorad, Hercules, CA) were used as molecular weight
markers. PAGE was performed at 100 V for 2 h. Recombi-
nant rat HO-1 protein (StressGen Biotechnologies Corp.,
Victoria, BD, Canada) and bovine muscle actin (Sigma)
were loaded as controls. Electrophoretical transfer of the
proteins onto a PVDF membrane (Immobilon-P, Millipore,
Bedford, MA) was performed at 16 V overnight at 4 C.
Membranes were incubated for 2 h in blocking buffer
(100 mM TriseHCl pH 7.5, 0.9% NaCl, 0.1% Tween-20, 2.5%
dry milk, 5% BSA).24 Immunoprobing was achieved in block-
ing buffer containing a rabbit polyclonal anti-HO-1 Ab
(1:2000, StressGen) and a rabbit anti-actin Ab (1:3000;
Sigma) for 1 h. A horseradish peroxidase-conjugated goat
anti-rabbit IgG (1:3000; Biorad) was used as secondary anti-
body, in a 1-h incubation. Positive signals were revealed
with the addition of a chemiluminescent substrate (Super-
Signal West Pico; Pierce), and exposure for 30 s to 5 min
on X-ray films (Pierce). Relative quantities of HO-1 protein
were determined using densitometry analysis (Alpha Inno-
tech Co., FluorChem digital imaging system, Alphaeasy-FC
32-bit 1-D analysis software, San Leandro, CA) and normal-
ized according to the actin content of individual samples.
Real-time quantitative RT-PCR analysis
Cytokine and HO-1 mRNA steady state levels were mea-
sured by real-time quantitative reverse transcription-poly-
merase chain reaction (RT-PCR) using the LightCycler
instrument (RocheeBoehringer Mannheim, Indianapolis, IN).
Extraction of mRNA was performed using the RNA NOW-LM
kit (Biogentex, Seabrook, TX). Synthesis of first strand
cDNA was performed from DNase-treated RNA (DNase I,
GibcoeLife Technology, Carlsbad, CA), utilizing the Super-
Script II RT kit (GibcoeLife Technology), with 25 ng/ml
oligo(dT)12e18 as primer. The RT product was amplified by
PCR in the LightCycler that allows real-time quantifica-
tion of the PCR product, based on the incorporation of
a fluorescent dye into the neosynthesized DNA and its
measurement at the end of each PCR cycle. Relative levelsof the initial transcript copy number in each cDNA sample
were calculated as previously described.25 Primer sequences
were created as follows: HO-1 forward 50-CGACAACCCCACC
AAGT-30, reverse 50-CCACGGTCGCCAACAG-30; IL-6 forward
50-AATCTGCTCTGGTCTTCTGGAGTTCCG-30, reverse 50-AGC
ATTGGAAGTTGGGGTAGGAAGGAC-30; TNF-a forward 50-
CCACGCTCTTCTGTCTACTGAACTTCG-30, reverse 50-CACTCC
AGCTGCTCCTCTGCTTGGTGG-30; GAPDH forward 50-TTCC
GTGTTCCTACCC-30, reverse 50-TCTTACTCCTTGGAGGC-30;
actin forward 50-GACTACCTCATGAAGATCC-30, reverse 50-
TCTCCTTCTGCATCCTGTC-30. Datawere analyzed as arbitrary
units calculating the ratio to the reference housekeeping
message (actin or GAPDH, as specified).
Histopathological assessment of tissue damage
Histopathological examination was performed in a blinded
manner by single pathologist (P.R.), on 4-mm-thick paraffin-
embedded sections stained with hematoxylin and eosin. A
score of 0eto 8 described by Park et al.6 was used for the
evaluation of intestinal mucosal injury. Score 0 indicated
normal mucosa; score 1: subepithelial space at the villi
tip; score 2: extended subepithelial space; score 3: epithe-
lial lifting along villous side; score 4: denuded villi; score 5:
loss of villus tissue; score 6: crypt layer infarction; score 7:
transmucosal infarction; and score 8: transmural infarction.
Inflammatory infiltrate was graded from 0 to 3, accord-
ing to the percentage of inflammatory cells detected on
a high power field of the histopathological specimen. Score
0: no signs of infiltration above normal; score 1: mild infil-
trate above normal (10e20%); score 2: moderate infiltrate
above normal (20e60%); and score 3: severe cellular infil-
trate above normal (>60%).
Myeloperoxidase activity assay
Myeloperoxidase (MPO) is an enzyme specific of polymor-
phonuclear neutrophil leukocytes (PMN) and assessment of
MPO activity provides an indirect measure of tissue PMN
cells infiltration.26 Tissues collected at selected time points
were snap-frozen and stored at 80 C until MPO activity
was assessed on protein extracts. Briefly, the frozen sam-
ples were homogenized with a mortar and pestle in potas-
sium phosphate buffer 0.05 M pH 5.4, containing 0.5%
hexadecyl-trimethyl-ammonium bromide (Sigma). They
were sonicated at 40 W for 30 s on ice before and after
three cycles of freezing (in liquid nitrogen) and thawing
(in a water bath at 37 C), and then incubated for 2 h at
60 C to inactivate other peroxidase activities.27 Superna-
tants were collected after ultracentrifugation of the
protein extract at 40,000 g for 15 min at 4 C, and were
assayed for MPO activity. Protein concentration of the
supernatants was assessed by a bicinchoninic acid-based
colorimetric quantitation assay (Pierce).
Myeloperoxidase activity was measured with a reaction
in which tissue supernatants (as source of MPO enzyme)
were mixed with 0.004% hydrogen peroxide (H2O2) in
80 mM sodium phosphate buffer, and 16 mM 3,30,5,50-tetra-
methylbenzidine was dissolved in dimethylsulfoxide (all
from Sigma). The change in absorbance (DA) at 652 nm
during a 3-min reaction was acquired using a Beckman
HO-1 upregulation reduces intestinal IRI 219spectrophotometer. One unit (U) of MPO enzyme activity
was defined as the amount of enzyme that utilized 1 mmol
of H2O2 per minute at 20
C, and calculated based on the
MPO extinction molar coefficient (3cZ 3.9 104 M1).28
Data were normalized to the protein concentrations for
each sample, and were expressed as U/min/mg of proteins.
Nitrate/nitrite serum levels
Nitric oxide (NO) plays a major role in mediating oxidative
stress. It is practically cumbersome to measure NO pro-
duction in biological samples because its half-life is very
short (seconds), but its by-products nitrites (NO2
) and ni-
trates (NO3
) are stable and can be measured in biological
fluids, providing a surrogate marker and quantitative indi-
cator of NO production.
Blood samples from control and treated animals were
collected at selected time points before the procedure,
after 60 min of ischemia, and after either 120 or 240 min of
reperfusion. They were centrifuged at 1000 g for 10 min at
room temperature, and the serum was stored at 80 C
until assessment. Nitrate/nitrite levels were measured as
previously described,29 using a modified Griess reaction.30,31
Briefly, serum was first centrifuged at 13,500 rpm for 10 min
at room temperature, and then the supernatant was depro-
teinized via filtration trough Ultrafree-MC 10,000 NMWL
filter units (Millipore, Billerica, MA). Samples diluted in
distilled water were incubated at 37 C for 20 min with
0.2 mM FAD, 2 mM NADPH (Sigma), and 8 U/ml nitrate re-
ductase (Roche) in 96-well flat bottom plates (Corning).
After a second 5-min incubation at 37 C with 5 mg/ml
L-lactate dehydrogenase (Roche) and 181 mM sodium py-
ruvate, the plates were chilled on ice, incubated at
4 C for 15 min in the presence of 12.3 mM sulfanilamide
dissolved in 0.1 M HCl (Sigma). A 10-min incubation at
room temperature in the dark with 1 mM naphthylenethy-
lenediamine was followed, and absorbance was measured
at 550 nm. An NaNO2 standard curve that was run in par-
allel and data were expressed as total concentration of
NO2
 in micromolar.
Statistical analysis
Data are expressed as mean standard deviation (SD). Sta-
tistical analysis was performed using analysis of variance
for individual groups. A correction for multiple comparisons
was performed using Bonferroni adjustment. Differences
were considered significant for p< 0.05.
Results
CoPP administration results in HO-1 upregulation
In order to assess the HO-1 upregulation that was induced
with the utilized treatment protocols, western blot analysis
was performed on tissue samples obtained 24 h after injec-
tion of saline, CoPP 10 or 20 mg/kg of body weight. Western
blot analysis of spleen extracts showed a substantial, dose-
dependent upregulation of HO-1, in animals treated with
10 and 20 mg/kg of CoPP (Fig. 1A). Densitometry analysisperformed on WB films showed that HO-1 protein expression
was 1.4- and 1.7-fold higher than baseline in animal that
received 10 and 20 mg/kg of CoPP, respectively (Fig. 1B).
Heme oxygenase-1 mRNA steady state expression was
analyzed by real-time quantitative RT-PCR performed on
intestinal samples obtained from control animals that
did not undergo IRI protocol (baseline), and after 240 min
of reperfusion in animals receiving either vehicle or CoPP
20 mg/kg 24 h before IRI protocol. Heme oxygenase-1
baseline levels in untreated animals were 0.11 0.02
arbitrary units; after 240 min of reperfusion they raised
to 0.62 0.24 in vehicle-treated animals (p< 0.05, 95%
CI: 0.84 to 0.05 vs. baseline), and 1.22 0.32 in animals
receiving 20 mg/kg of CoPP (p< 0.001 95% CI: 1.49
to 0.59 vs. baseline; p< 0.01 95% CI: 1.07 to 0.15 vs.
controls at same time point) (Fig. 2). These data showed
that with our intestinal IRI protocol a substantial upregula-
tion of HO-1 mRNA steady state level was induced in control
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Figure 1 Western blot (WB) densitometry analysis. To assess
systemic induction of heme oxygenase-1 (HO-1) upregulation,
spleens obtained from control (0Z baseline-vehicle alone)
or cobalt protoporphyrin (CoPP)-treated animals (CoPP 10Z
10 mg/kg; CoPP 20Z 20 mg/kg) were obtained 24 h after treat-
ment. WB analysis was performed on protein extract and re-
vealed by immunoblotting with anti-HO-1 and anti-b-actin
antibodies. Densitometry analysis shown as fold increase of
HO-1 protein is expressed in arbitrary units after normalization
to b-actin.
220 N. Wasserberg et al.animals (5.5-fold over baseline), and that pre-treatment
with a single IP injection of 20 mg/kg of CoPP resulted in
higher HO-1 upregulation after IRI (10.9-fold over baseline,
2-fold over controls).
CoPP induced HO-1 results in reduced
histopathological pattern of tissue injury
Ischemic insult results in a series of morphological alter-
ations of the injured intestine after reperfusion, including
mucosal damage and inflammatory cell infiltrate that can
be assessed to evaluate the extension of the tissue damage.
Mucosal damage and intestinal inflammatory infiltrate
assessed on specimens collected after 240 min of reperfu-
sion were reduced in the intestine of animals receiving
20 mg/kg of CoPP, when compared to controls (Table 1)
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Figure 2 Hemeoxygenase-1 (HO-1)mRNAexpression in the in-
testine. HO-1mRNA steady state levels were assessed on control
animals not undergoing IRI protocol (baseline), and in control and
CoPP-treated (nZ 4) animals after 240 min of reperfusion.
Ischemia reperfusion injury (IRI) induced upregulation of HO-1
expression in control animals (*p < 0.05, 95% CI: 0.84
to 0.05 vs. basal levels), which was dramatically enhanced by
the administration of 20 mg/kg of CoPP (**p < 0.01, 95%
CI: 1.07 to 0.15; ***p < 0.001, 95% CI: 1.49 to 0.59;
p< 0.0003, ANOVA). Data are expressed as arbitrary units calcu-
lated by normalizing HO-1 expression to GADPH.(mucosal damage: 2.0 0.9 and 0.2 0.2, respectively)
and (intestinal inflammatory infiltrate: 3.9 0.5 and 1.1
0.4, respectively). However, these results were not statisti-
cally significant (pZ 0.8, ANOVA, and pZ 0.2, ANOVA,
respectively). Fig. 3 demonstrates the histological differ-
ence between study and controls groups after 240 min of
reperfusion. Reduced mucosal damage was not observed
after 120 min or in the animals receiving lower CoPP dose.
HO-1 upregulation is paralleled by a lower mRNA
steady level expression of the proinflammatory
cytokine IL-6
IL-6 production is induced upon injury as a response to
inflammation and stress. Local synthesis and release of IL-6
may result in amplification of the inflammatory reaction via
its chemotactic properties. After induction of ischemia and
240 min of reperfusion IL-6 steady state mRNA expression in
the intestine of vehicle-treated animals was 18.2-fold higher
than basal levels (no ischemia) (2.24 0.79 vs. 0.12 0.14,
respectively; p 0.01, 95% CI: 3.5 to 0.88). In contrast,
IL-6 mRNA levels 240 min after reperfusion were only 8.7-
fold higher than baseline when HO-1 upregulation was
induced by CoPP administration before IRI (1.06 0.59;
pZ 0.12, 95% CI: 2.19 to 0.29 vs. baseline, p 0.05, 95%
CI: 0.09e2.25 vs. controls, p< 0.002, ANOVA; Fig. 4). This
statistically significant difference in IL-6 reduction was not
observed after 120 min of reperfusion.
Myeloperoxidase activity is significantly
reduced in treated animals
Basal MPO activity in non-manipulated animals was
0.07 0.02 U/mg of protein, and significantly increased
120 min (0.24 0.01) and 240 min (0.22 0.06) after reper-
fusion in vehicle-treated animals (p< 0.001, 95% CI: 0.21
to 0.10 and p< 0.001, 95% CI: 0.21 to 0.09 vs. base-
line, respectively). Pre-treatment of the animals with
10 mg/kg of CoPP to induce HO-1, consistently resulted in
a clinical reduction of MPO levels after both 120 min
(0.17 0.9, pZ 0.2) and 240 min of reperfusion (0.08
0.06, p< 0.01, 95% CI: 0.06e0.23) when compared to
their non-treated counterparts. Similarly, the administra-
tion of 20 mg/kg of CoPP showed lower MPO levels afterTable 1 Mucosal damage and intestinal inflammatory infiltrate scores
Group N Treatment Ischemia
(min)
Reperfusion
(min)
Mucosal damage
(score)
Inflammatory
infiltrate (score)
1 6 Vehicle 0 (baseline) 0 (baseline) 1.4 0.7 0.3 0.4
2 5 Vehicle 60 120 3.0 0.6 0.9 0.5
3 5 CoPP 10 mg/kg 60 120 3.2 0.4 1.0 0.5
4 5 CoPP 20 mg/kg 60 120 2.9 0.3 0.8 0.4
5 7 Vehicle 60 240 3.9 0.5 1.1 0.4
6 5 CoPP 10 mg/kg 60 240 3.1 0.8 0.9 0.3
7 5 CoPP 20 mg/kg 60 240 2.0 0.9 0.2 0.2
A reduction in mucosal injury and inflammatory infiltrate scores was demonstrated after 240 min of reperfusion, however, this reduction
was not statistically significant.
HO-1 upregulation reduces intestinal IRI 221both 120 min (0.15 0.06; pZ 1.1 vs. CoPP 10 mg/kg and
untreated groups) and 240 min (0.07 0.06; p< 0.01, 95%
CI: 0.07e0.24 vs. untreated, and pZ 0.85 vs. CoPP
10 mg/kg-treated group) of reperfusion (Fig. 5).
Figure 3 Histopathological pattern of the intestine. Hema-
toxylin and eosin staining of intestinal samples obtained from
animals that underwent ischemia reperfusion injury (IRI) proto-
col with 240 min of reperfusion and received either no treat-
ment or 20 mg/kg of CoPP 24 h before. IRI induced dramatic
alteration of mucosal integrity in untreated animals (panel A),
which were prevented by pre-treatment with 20 mg/kg of
CoPP to induce HO-1 upregulation (panel B). (Villi architecture:
black arrows; inflammatory infiltrate: gray arrows.)
Figure 4 Analysis of IL-6 mRNA expression in the intestine:
baseline mRNA steady state levels assessed by real time quanti-
tative RT-PCR on intestines obtained at baseline (time 0 vehicle
only) from naı¨ve animals (nZ 3), and after 240 min of reperfu-
sion in control and cobalt protoporphyrin (CoPP)-treated ani-
mals. Data are expressed as mean arbitrary unit (SD) after
normalization to b-actin. p< 0.002, ANOVA; *p 0.01, 95% CI:
3.5 to 0.88; **p 0.05, 95% CI: 0.09e2.25;*** p 0.05, 95%
CI: 2.19 to 0.29.Treated animals show a reduction of NO
metabolites serum levels
Assessment of NO by-products was performed on sera
collected at selected time points, in order to determine
the effects of the treatments on NO production in this
model. Basal nitrate/nitrite levels in sera collected before
IRI were 7.9 1.2 mM/ml in controls, 8.4 0.5 and
7.5 1.0 mM/ml in animal receiving 10 or 20 mg/kg of
CoPP, respectively (pZ 1.6). Serum nitrate/nitrite levels
significantly increased following IRI in all non-treated
groups (p< 0.0001, ANOVA) (Fig. 6). A statistically signifi-
cant reduction in NO by-products level was observed only
in the group that received 20 mg/kg of CoPP 240 min after
reperfusion when compared to untreated animals (8.2 1.6
and 17.3 4.2 mM/ml, respectively; p< 0.01, 95% CI: 5.58e
12.75) (Fig. 6).
Discussion
Induction of HO-1 upregulation has been documented in
a variety of cell subsets and tissues following stress
conditions.15,32e34 Additional evidence on the important
role of HO-1 in the modulation of inflammation is provided
by the observation that mice lacking HO-1 protein have in-
creased sensitivity to oxidant injury,35 and share some
pathological features with HO-1 deficiency in humans.36
Amongst other stimulants, NO, cytokines, heme, and heavy
metals can induce HO-1 upregulation as a result of modulat-
ing HO-1 gene expression.15e18,32
In the present study we report on the protective effect
of CoPP-induced HO-1 to reduce intestinal IRI. Expression of
HO-1 mRNA steady state levels in the intestine of control
animals was increased after injury, suggesting that HO-1
upregulation might be one of the constitutive mechanisms
of defense of the organ during IRI. These data are
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
Baseline 120 min 240 min
M
P
O
 
A
c
t
i
v
i
t
y
 
(
U
/
m
g
 
p
r
o
t
')
Vehicle
CoPP 10
CoPP 20
**
*
Figure 5 Intestinal myeloperoxidase (MPO) activity. MPO was
assessed on protein extracts obtained from treated and control
groups at 120 and 240 min after reperfusion, and from naı¨ve an-
imals (baseline). IRI induced a dramatic increase in MPO activity
in control animals measurable at both 120 and 240 min. Pre-
treatment of the animals with either dose of cobalt protopor-
phyrin (CoPP) resulted consistently in MPO levels lower than
untreated animals after 120 min and 240 min of reperfusion. Data
are expressed as average  SD. p < 0.01, ANOVA; *p  0.01,
95% CI: 0.06e0.23; **p 0.01, 95% CI: 0.07e0.24.
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intermittent short ischemic insults before hemorrhagic
shock resulting in the prevention of systemic inflammatory
response.37 Administration of CoPP 24 h before IRI effi-
ciently induced HO-1 upregulation resulting in significantly
higher HO-1 mRNA steady state levels when compared to
spontaneously IRI-induced increased HO-1 levels. Addition-
ally, CoPP treatments resulted in induced upregulation of
HO-1 protein expression in the spleen in a dose-dependent
fashion, confirming the systemic effect of the treatments.
Pharmacological induction of HO-1 upregulation by means
of CoPP has been widely used to prevent or reduce inflam-
mation-mediated injury.16,19,38,39 It is conceivable that
both systemic and local upregulations of HO-1 might con-
tribute to the observed protective effects from intestinal
IRI in our model of chemically induced HO-1 upregulation.
This assumption is further supported by previous data,
which demonstrated that the inhibition of HO-1 by means
of Tin, or Zinc-protoporphyrine40 abrogated the protective
effect of HO-1. Potential pleiotropic effects of CoPP treat-
ment mediated through mechanism different from HO-1
upregulation cannot be excluded in our study. Evidence of
its effects on inflammation and immunity have been always
associated with HO-1 induction.16,38 Impairment of macro-
phage function,38 inhibition of lymphocyte response to
mitogen-stimulation in vitro, can also be achieved with
CoPP treatment both in vitro and in vivo in experimental
animals.38,39
Various inflammatory mediators are released by the
injured endothelium and by recruited PMNs upon IRI,41 in-
cluding the proinflammatory cytokine IL-6.28 In our experi-
mental model HO-1 upregulation induction by CoPP was
paralleled by a statistically significant reduction of inflam-
mation markers. Following IRI, a substantial increase in
intestinal mRNA steady level of IL-6 was measured in control
animals, while it was significantly reduced in the intestine
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Figure 6 Serum nitric oxide metabolites analyzed by using
a modified Griess reaction. Basal levels in sera collected before
ischemia reperfusion injury (IRI). Serum nitrate/nitrite levels
significantly increased following ischemic protocol and reper-
fusion in all non-treated groups (p< 0.0001, ANOVA). A statis-
tically significant reduced nitrate/nitrite level was observed
after 240 min of reperfusion in the group receiving 20 mg/kg
of cobalt protoporphyrin (CoPP) when compared to untreated
animals. *p< 0.01, 95% CI: 5.58e12.75;*p< 0.0001, ANOVA.
Data are expressed as mM/ml (average SD) of NO2/NO3.of animals receiving 20 mg/kg of CoPP, when measured
240 min after reperfusion. Intestinal MPO activity, assessed
as an indirect measure of PMN cell infiltrate, was markedly
reduced in animals receiving CoPP treatments, when com-
pared to vehicle-treated controls. The reduction of MPO ac-
tivity in treated animals was more dramatic 240 min after
reperfusion. Corresponding to MPO activity reduced pattern
of inflammatory cell infiltrate and mucosal damage was ob-
served by histopathological analysis.
Oxidative stress plays a major role in the extension of
organ injury upon IRI.1,6e11 Nitric oxide might exert a dual
effect during intestinal inflammation, being both beneficial
in reducing tissue damage, and deleterious in the course of
its reaction with superoxide anion to form peroxynitrite
anion.42 In the present study, increased NO metabolites
(NO2/NO3) were measured in the sera of control animals
240 min after reperfusion. A significant reduction of NO2/NO3
was observed in the animals treated with 20 mg/kg of
CoPP at the same time point. This reduction in NO by-
products correlated well with the observed reduction in
intestinal tissue damage, suggesting a beneficial effect pos-
sibly caused by the inhibition of NO production through
CoPP-mediated HO-1 upregulation.
Collectively, our data suggest that CoPP-induced HO-1
upregulation substantially reduces intestinal damage fol-
lowing IRI in a rat model. This was paralleled by a decreased
inflammatory reaction which was more profound when high
dose of CoPP (20 mg/kg) was given 24 h before IRI insult.
Consistent with previous reports,40,43 the present study
supports the fact that longer time of reperfusion is associ-
ated with increased tissue injury in untreated animals. In
a model of intestinal warm IRI similar to the one utilized
in the present study, Koksoy et al.42 reported mortality
rates of 28% and 46% after 2 h and 4 h of reperfusion, re-
spectively. Interestingly, our data indicate that the benefi-
cial effects of the pre-treatment with CoPP are more
pronounced when the analysis is performed after 240 min
of reperfusion. It is therefore conceivable that the CoPP-
mediated HO-1 upregulation may be capable of mediating
the earlier recovery of the intestine following IRI observed
in our study. Our results are in agreement with recent data
published during the preparation of the current study. In
that article, Attuwaybi et al.43 described the protection
effect of Hemin induced HO-1 upregulation by showing sig-
nificant reduction in the intestinal mucosal injury and im-
proved intestinal transit following 60 min of ischemia and
6 h of reperfusion. Their results failed to demonstrate a de-
crease in MPO activity which was attributed to the ‘opti-
mal’ time of reperfusion. The increasing body of evidence
supporting the key role of HO-1 in inflammation and cyto-
protection16,44 makes this molecule and its by-products
suitable candidates for strategies aiming at the reduction
of IRI.45,46 In the present study we have demonstrated
that CoPP-induced HO-1 upregulation protects the rat
intestine from warm ischemia and reperfusion injury. Strat-
egies aiming at the induction of HO-1 upregulation might re-
sult helpful in the treatment of intestinal injuries associated
with intestinal obstruction, abdominal aortic aneurysm re-
pair, IRI associated intestinal trauma and blast injury, and
other causes related to mesenteric ischemia. In the case
of organ transplantation this approach may have a dramatic
impact in reducing the occurrence of primary non-function
HO-1 upregulation reduces intestinal IRI 223of the transplanted organ. Furthermore, cytoprotection in-
duction may minimize graft immunoreactivity, potentially
resulting in improved graft function. Further understanding
of the molecular mechanisms by which CoPP-induced HO-1
upregulation exerts its protective effects might allow for
the implementation of targeted strategies clinically
applicable.
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